Your Health, We Care
On November 17, 2023, the U.S. Food and Drug Administration (FDA) approved Tucatinib (Capivasertib) in combination with Fulvestrant for the treatment of patients with advanced hormone receptor-positive breast cancer.
On November 17, 2023, AstraZeneca’s capivasertib in combination with Faslodex (f···【more】
Release date：2026-01-13Recommended：30
On June 12, 2023, the New Drug Application (NDA) for capivasertib in combination···【more】
Release date：2026-01-13Recommended：29
